YD Bio

YD Bio FCF/Debt

The Free Cash Flow to Debt Ratio of YD Bio (YDES) as of Nov 3, 2026 is -118,816.09 %. In the previous year, Free Cash Flow to Debt Ratio was -21,049.93 % — a change of 464.45% (lower).

FCF/Debt

-118,816.09 %

YoY

464.45%

Last updated:

Free Cash Flow to Debt Ratio of YD Bio is 2025 -118,816.09 % . Free Cash Flow to Debt Ratio of YD Bio was 2024 -21,049.93 % . It decreases by 464.45% lower compared to the previous year.

The YD Bio FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2023
-117.60 USD
Jan 1, 2024
-21,049.93 USD
Jan 1, 2025
-118,816.09 USD
The YD Bio FCF/Debt history
YEARFCF/DebtYoY
-118,816.09 %+464.45%
-21,049.93 %+17,800.36%
-117.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

YD Bio Stock analysis

What does YD Bio do? YD Bio Ltd is a Taiwan-based company focused on early cancer detection tools, ophthalmologic products for dry eye conditions, and exosome-based therapeutics for complex diseases. The company generates revenue through its core areas of non-invasive cancer detection solutions, dry eye treatment products, and exosome-based therapies, targeting healthcare providers and patients seeking advanced medical solutions. Its products are designed to improve patient outcomes and quality of life by offering accessible diagnostic and therapeutic options in the healthcare sector. The company’s business model emphasizes integrating cutting-edge science with accessible solutions, positioning itself as a provider of transformative healthcare innovations. By developing non-invasive diagnostic tools for early cancer detection, specialized ophthalmologic treatments, and next-generation cell therapies, YD Bio serves medical professionals and patients globally. Its focus on pioneering solutions aligns with the growing demand for early diagnosis and advanced treatment options in the healthcare industry. YD Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about YD Bio stock

Free Cash Flow to Debt Ratio of YD Bio is -118,816.09 % in 2025.

Free Cash Flow to Debt Ratio of YD Bio changed from -21,049.93 % to -118,816.09 %, representing a 464.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio YD Bio since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's YD Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — YD Bio

All Key Metrics — YD Bio